Immune cell function assay and T lymphocyte counts lack association with rejection or infection in pediatric heart transplant recipients
Clinical Transplantation2022Vol. 37(2), pp. e14858–e14858
Citations Over Time
Justin K. Chen, David M. Salerno, Heather Corbo, Benjamin S. Mantell, Marc E. Richmond, A. Rothkopf, Irene D. Lytrivi
Abstract
No association was found between these immune markers and adverse outcomes. In the absence of larger pediatric studies justifying the role of these tests in identifying elevated risk profiles post OHT, we do not recommend their routine use.
Related Papers
- → Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus(2004)165 cited
- → A pilot study of immunosuppression resumption following BK viremia resolution(2020)5 cited
- → Alemtuzumab (Campath-1H) Combined With Tacrolimus in Intestinal and Multivisceral Transplantation(2005)10 cited
- → A Pilot Study of Immunosuppression Resumption Following BK Viremia Resolution(2018)1 cited
- → The use of alemtuzumab after non-selective immunosuppression in a patient with highly active rapidly progressive remitting multiple sclerosis(2019)